FDA approves Mounjaro heart-risk indication and keeps 2.5 mg dose on the label

Two changes to Mounjaro's label took effect Aug. 27, 2026: a new indication to lower cardiovascular risk in adults with type 2 diabetes, and revised dosing language that allows the 2.5 mg weekly dose to be used for ongoing blood sugar control ^[1][3]. The FDA logged the decisions as two supplements, S-044 for the new indication and S-045 for the new dosing regimen ^[1].

The heart indication

The label now states that Mounjaro (tirzepatide) can be used "to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events" ^[4]. The drug has been marketed since 2022 to improve blood sugar in adults and children 10 and older with type 2 diabetes ^[4][5].

The evidence comes from SURPASS-CVOT, a randomized, double-blind Phase 3 trial that assigned 13,299 people at 640 sites in 30 countries ^[5]. All had type 2 diabetes and established atherosclerotic cardiovascular disease. Half received Mounjaro at 15 mg or the highest dose they could tolerate; half received Trulicity (dulaglutide) 1.5 mg, a GLP-1 medicine already labeled to cut cardiovascular risk ^[5]. Follow-up ran a median of 210.1 weeks, about four years ^[5].

Mounjaro was non-inferior to dulaglutide for the composite of cardiovascular death, heart attack or stroke, with an 8% lower rate of those events and an estimated hazard ratio of 0.92 (95.3% CI: 0.83, 1.01) ^[5]. Superiority to dulaglutide was not established ^[5]. Lilly said the study was the first cardiovascular outcomes trial to compare two incretin medicines against each other rather than against a placebo, and that full results appeared in the New England Journal of Medicine ^[5].

The dosing adjustment

The FDA letter describes S-045 as an update "to indicate that the 2.5 mg dose of tirzepatide can be used for ongoing glycemic control in patients with type 2 diabetes mellitus" ^[3]. The revised label calls 2.5 mg once weekly the starting dose and says the dose goes up in 2.5 mg steps after at least four weeks "if additional glycemic control is needed," to a maximum of 15 mg weekly in adults and 10 mg in children 10 and older ^[4].

Documents released with the approval do not say how many patients stay at 2.5 mg or for how long. They cover Mounjaro only; they do not address Zepbound, the weight-management version of tirzepatide ^[1][3].

Nothing in the safety sections changed. Mounjaro still carries a boxed warning noting that tirzepatide causes thyroid C-cell tumors in rats and that it is unknown whether the same happens in people; the drug is not for anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[4]. Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain were the most common side effects, each reported in at least 5% of patients ^[4]. Lilly reported that gastrointestinal events in the trial were generally mild to moderate and clustered during dose increases ^[5].

Why it matters for patients

Adults with type 2 diabetes and elevated heart risk now have a label that names a cardiovascular benefit, not just glucose lowering. That may come up in conversations with prescribers and in coverage decisions, though whether insurers will treat the new indication differently has not been reported. Trulicity, the drug Mounjaro was tested against, also carries a cardiovascular risk-reduction label ^[5]. The comparison was not against placebo; the approval reflects that Mounjaro performed no worse than an existing treatment, with a lower event rate that did not reach statistical superiority ^[5].

For someone already on 2.5 mg weekly, the dosing change is the more practical piece. The label no longer frames that strength as a way station on the path to a higher dose; it now says the dose can be used to maintain blood sugar control ^[3][4]. It still leaves the decision about raising the dose to individual circumstances, and it sets no rule for who should remain at 2.5 mg ^[4].

What happens next

The approval letter gives Lilly deadlines: submit updated structured product labeling within 14 days, file a statement of intent to comply with promotional-material rules within 7 days, and submit patent information within 30 days ^[3]. The FDA waived pediatric study requirements for S-044, saying the necessary studies are impossible or highly impracticable because the condition rarely or never occurs in children, and exempted S-045 from that requirement ^[3]. Lilly says applications based on SURPASS-CVOT are under review in other countries outside the U.S. ^[5].